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Abstract
The aim of this study was to determine if severity assessment tools (general severity of illness and community-acquired pneumonia spe-
cific scores) can be used to guide decisions for patients admitted to the intensive care unit (ICU) due to pandemic influenza A pneumo-
nia. A prospective, observational, multicentre study included 265 patients with a mean age of 42 (±16.1) years and an ICU mortality of
31.7%. On admission to the ICU, the mean pneumonia severity index (PSI) score was 103.2 ± 43.2 points, the CURB-65 score was
1.7 ± 1.1 points and the PIRO-CAP score was 3.2 ± 1.5 points. None of the scores had a good predictive ability: area under the ROC
for PSI, 0.72 (95% CI, 0.65–0.78); CURB-65, 0.67 (95% CI, 0.59–0.74); and PIRO-CAP, 0.64 (95% CI, 0.56–0.71). The PSI score (OR,
1.022 (1.009–1.034), p 0.001) was independently associated with ICU mortality; however, none of the three scores, when used at ICU
admission, were able to reliably detect a low-risk group of patients. Low risk for mortality was identified in 27.5% of patients
using PIRO-CAP, but above 40% when using PSI (I–III) or CURB65 (<2). Observed mortality was 13.7%, 13.5% and 19.4%, respectively.
Pneumonia-specific scores undervalued severity and should not be used as instruments to guide decisions in the ICU.
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Introduction
The prevalence of severe community-acquired pneumonia
(CAP), defined by the need for intensive care unit (ICU)
admission [1,2], ranges from 6.6% to 16.7% [3–7]. Its mortal-
ity is high, with pneumonia/influenza being the eighth leading
cause of death in the USA [8].
2007 Guidelines for the management of patients with CAP
published by the American Thoracic Society (ATS) and the
Infectious Diseases Society of America (IDSA) [1], suggest
the use of severity of illness scores such as the Pneumonia
Severity Index (PSI) [9] and CURB-65 [10] in addition to
clinical judgement to help physicians to decide the most
appropriate site of care. Both scores have been validated at
the emergency department and were designed to predict
30 day-mortality. They mainly identify patients with a low
risk of mortality that can be safely managed in an outpatient
setting. In 2009, Rello developed a severity assessment score
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for CAP patients based on the PIRO concept [11]. This
PIRO-CAP score performed well as a 28-day mortality pre-
diction tool in CAP patients requiring ICU admission, with a
better performance than either the Acute Physiology and
Chronic Health Evaluation (APACHE) II score [12] or the
ATS/IDSA criteria [1] in this subset of patients.
Primary viral pneumonia is recognized as the most com-
mon and also the most severe pulmonary manifestation of
2009 Influenza A (H1N1) because it is associated with high
morbidity and mortality. The increased prevalence of this
condition may necessitate the use of triage in order to prior-
itize ICU resources; however, the accuracy of the available
severity of illness scores in this condition is unknown. Our
objective was to assess which scoring system was best able
to predict ICU mortality in patients admitted to the ICU due
to 2009 Influenza A (H1N1) infection. A secondary aim was
to identify variables associated with poor outcome in the
subset of patients with an estimated risk of death below
3.6%.
Methods
This was a prospective, international, multicentre, observa-
tional study in patients with severe CAP due to the 2009
Influenza A (H1N1) virus admitted to ICUs of 33 countries.
Data were prospectively collected through a web-based
eCRF: the European Society of Intensive Care Medicine Influ-
enza A (H1N1)v Registry. Ethical approval was sought and
obtained prior to any patients being entered into the regis-
try. The need for informed consent was waived due to the
observational nature of the study. There were 394 patients,
of whom we excluded 77 due to unavailability of data to cal-
culate the three pneumonia-specific scores or unknown out-
come at ICU discharge. Patients (n = 52) who presented
with acute exacerbations of asthma or chronic obstructive
pulmonary disease (COPD) were also excluded from this
analysis (Fig. 1).
CAP due to the 2009 Influenza A (H1N1) virus was
defined as a patient fulfilling ATS/IDSA criteria for CAP [1]
and having a positive respiratory sample for the virus by
reverse transcriptase polymerase chain reaction or viral cul-
ture. Primary viral pneumonia was defined in patients pre-
senting during the acute phase of influenza virus illness with
ARDS and unequivocal alveolar opacification with negative
respiratory and blood bacterial cultures.
Data were collected to describe the severity of illness of
each patient on admission to ICU. These data included
baseline descriptors of demographics, co-morbid conditions
and also physiological status and organ supports. The simpli-
fied acute physiology score (SAPS 3) [13] and the APACHE
II score [12] were calculated according to the original
descriptions.
Severity of CAP was evaluated using the PSI [9], CURB-65
[10] and PIRO-CAP [11] scores, which were calculated at
the time of ICU admission. Patients were classified according
to the original scores and were identified as having a low
risk for mortality if the predicted mortality was between 0
and 3.6% [9–11]. This low risk of mortality corresponded to
a PSI class of I, II or III, a CURB-65 score of 0 or 1, or a
PIRO-CAP between 0 and 2. Patients with a PSI class ‡ IV,
CURB-65 ‡ 3 or PIRO-CAP ‡ 4 were classified as high-risk
patients.
Statistical analysis was performed using PASW 18.0 soft-
ware (Chicago, IL, USA). The outcome variable of mortality
was defined as all-cause mortality at the time of ICU dis-
charge. Discrete variables are described as counts (%) and
continuous variables as the mean with standard deviation
(SD) or medians with 25th–75th interquartile range (IQR),
as appropriate. Chi-square or Fisher’s exact tests were used
to compare categorical variables and Mann–Whitney U-tests
for continuous variables. Receiver operating characteristic
curves (ROC) were generated to compare the overall
predictive accuracy of the scores for mortality, and the area
under the ROC curves (aROC) was calculated. Variables
associated with mortality were defined if a two-sided p
value was £0.05; 95% confidence intervals were calculated.
To determine factors potentially associated with ICU
outcome, a multivariate logistic regression analysis was
performed that included all significant variables from the
univariate analysis, which were deemed clinically important
before or at ICU admission. The sensitivity, specificity, posi-
tive predictive value (PPV) and negative predictive value
(NPV) for each score were calculated according to standard
criteria.
Patients included in the
ESICM H1N1 registry
n = 394
Patients excluded
n = 129
Studied patients
n = 265
Incomplete dataset to calculate the
three pneumonia specific scores or
unknown ICU outcome
n = 77 
Acute exacerbations of
asthma or COPD
n = 52 
FIG. 1. Flowchart of enrolled patients.
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Results
Two hundred and sixty-five patients were enrolled in the
study. These patients were from 31 different countries, from
four continents. The main recruiting countries were: Portugal
(55 cases), Spain (39 cases), Italy (39 cases), the UK (19
cases) and Argentina (18 cases). Patients were admitted to
the hospital and to the ICU 5 (±4.66) and 7 (±5.87) days,
respectively, after the onset of the symptoms.
The patients were 54% male with a mean age of 42 years
(±16.1) and had an ICU admission SAPS 3 score of 54
(±15.9) and an APACHE II score of 22 (±8.7). No co-mor-
bidity was present in 69 (26%) patients and 86 (33%) had
associated bacterial pneumonia. Median ICU length of stay
was 12 days (IQR, 6–22 days) and 84 (31.7%) patients died
whilst in the ICU. Characteristics of the study population
according to ICU outcome are shown in Table 1.
The number of patients and deaths in each class/score
according to PSI, CURB-65 and PIRO-CAP with their actual
and predicted mortality rates are shown in Table 2.
The mean PSI score was 103.2 ± 43.2 points, and was sig-
nificantly related to ICU survival (survivors 92.6 ± 41.1 vs.
non-survivors 126.1 ± 38.9; p <0.001). The relationship
between the increase in the PSI class and the corresponding
increase in ICU mortality was smooth (class I and II, 8.6%
ICU mortality; class III, 22%; class IV, 38%; class V, 52%; p
<0.001). The predictive accuracy of the PSI score, as evalu-
ated by the aROC, was reasonable: 0.73 (95% CI, 0.67–0.78).
The mean CURB-65 in this group of patients was
1.7 ± 1.1 points and it was also significantly related to ICU
survival (survivors 1.5 ± 1.1 vs. non-survivors 2.2 ± 1.1; p
<0.001). Although there was a smooth relationship between
an increasing score and ICU mortality (0 points, 13.9% ICU
mortality; 1 point, 22.1%; 2 points, 33.3%; 3 points, 45.9%;
‡4 points, 66.7%; p <0.001), the accuracy, as evaluated by
the aROC, was only 0.67 (95% CI, 0.59–0.74).
The PIRO-CAP score was on average 3.2 ± 1.5 points and
it was significantly lower in ICU survivors (2.9 ± 1.5 vs.
3.7 ± 1.3; p <0.001). As in the other scores, the relationship
between the increase in the score and the corresponding
increase in ICU mortality was smooth (0–2 points, 13.7%
TABLE 1. Characteristics of study
population split up by intensive
care outcome
Whole
population
(n = 265)
Survivor
(n = 181)
Non-survivor
(n = 84) p
Age 42 ± 16.1 41 ± 15.8 45 ± 16.5 0.068
Gender, male (%) 142 (54) 96 (53) 46 (55) 0.794
SAPS 3 score 54 ± 15.9 51 ± 13.9 60 ± 18.2 <0.001
APACHE II score 22 ± 8.7 20 ± 8.0 25 ± 8.9 <0.001
Co-morbidities (%) 196 (74) 132 (72.9) 64 (76.2) 0.573
Diabetes mellitus 34 (12.8) 24 (13.3) 10 (11.9) 0.759
Asthma 11 (4.2) 7 (3.9) 4 (4.8) 0.747
COPD 14 (5.3) 10 (5.6) 4 (4.8) 1.0
Other chronic pulmonary disease 13 (4.9) 6 (3.3) 7 (8.3) 0.122
Cerebrovascular disease 7 (2.6) 4 (2.2) 3 (3.6) 0.682
Smoker 73 (27.7) 54 (30) 19 (22.6) 0.212
Arterial hypertension 64 (24.2) 45 (24.9) 19 (22.6) 0.691
Haematological neoplasia 24 (9.1) 13 (7.2) 11 (13.2) 0.119
Chronic hepatic disease 6 (2.3) 3 (1.7) 3 (3.6) 0.385
Autoimmune disease 7 (2.6) 5 (2.8) 2 (2.4) 1.0
Immunosuppression 3 (5.7) 2 (6.3) 1 (4.8) 1.0
Chronic renal failure 14 (5.3) 10 (5.5) 4 (4.8) 1.0
Corticotherapy 25 (9.5) 16 (8.9) 9 (10.7) 0.637
Chemotherapy 14 (5.3) 6 (3.3) 8 (9.5) 0.072
Pregnancy 16 (6) 13 (7.2) 3 (3.6) 0.251
Post-partum 6 (2.3) 6 (3.3) 0 (0) 0.181
Alcohol abuse 15 (5.7) 12 (6.6) 3 (3.6) 0.401
Congestive heart failure 9 (3.4) 5 (2.8) 4 (4.8) 0.471
Obesity (BMI > 30 kg/m2) 24 (9.1) 14 (7.7) 10 (11.9) 0.271
Time from onset of symptoms to
Hospital admission (days) 5 ± 4.7 4.8 ± 4.3 5.6 ± 5.4 0.234
ICU admission (days) 6.8 ± 5.9 6.6 ± 5.6 7.3 ± 6.3 0.352
Mechanical ventilation, days 12 (8–20) 12 (7–21) 13 (8–18) 0.736
ICU length of stay, days (median) 12 (6–22) 12 (5–22) 12 (7–23) 0.503
Associated clinical conditions (%)
Bacterial pneumonia (n = 261) 86 (33) 60 (33.9) 26 (31) 0.636
Other infection (n = 260) 11 (4.2) 6 (3.4) 5 (6.0) 0.341
Septic shock (n = 261) 121 (46.4) 66 (37.3) 55 (65.5) <0.001
Acute coronary syndrome (n = 261) 5 (1.9) 3 (1.7) 2 (2.4) 0.658
Acute renal failure (n = 261) 49 (18.8) 29 (16.4) 20 (23.8) 0.151
Acute consciousness change (n = 261) 80 (30.7) 42 (23.7) 38 (45.2) <0.001
Rhabdomyolysis (n = 260) 41 (15.8) 20 (11.4) 21 (25) 0.005
Ventilatory strategies (%)
Invasive mechanical ventilation (n = 263) 188 (75.3) 116 (64.8) 82 (97.6) <0.001
Non-invasive ventilation (n = 260) 84 (32.3) 65 (36.7) 19 (22.7) 0.026
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ICU mortality; 3 points, 32.5%; 4 points, 40.3%; ‡5 points,
45.8%; p 0.001) and the discriminatory power, as evaluated
by the aROC, was only 0.64 (95% CI, 0.58–0.71).
The PSI score was the best predictor of mortality, with a
reasonable discriminatory power (aROC, 0.73; 95% CI, 0.65–
0.81) in patients with only primary viral pneumonia. On the
other hand, CURB-65 showed the best accuracy (aROC,
0.77; 95% CI, 0.66–0.87) when bacterial co-infection was
considered. The discriminatory power of PSI and PIRO-CAP
was similar in patients with or without bacterial co-infection;
however, in patients with bacterial co-infection the discrimi-
natory power of CURB-65 and APACHE II significantly
improved from 0.62 to 0.77 and from 0.65 to 0.75, respec-
tively. On the opposite side, the accuracy of SAPS 3
decreased from 0.70 to 0.57 (Table 3).
In the overall population, a PIRO-CAP score ‡ 1 had the
highest sensitivity (96.4%) whereas CURB-65 = 5 and PIRO-
CAP 8 had the highest specificity (99.5%). All scores had low
PPV, with CURB-65 ‡ 4 reaching the highest value (63.6%).
The best NPV was associated with PSI ‡ 3 (91.4%) (Table 4).
The only variables independently associated with ICU mor-
tality, by multivariate analysis, were the PSI score (OR 1.022
(1.009–1.034), p 0.001) and the need for mechanical ventila-
tion at ICU admission (OR 20.629 (4.263–99.83), p <0.001).
Patients were classified at low risk of mortality according
to the original scores. None of the scores were good at
classifying this low-risk group. The PSI score identified 111
patients (41.9%) to be at a low risk of death, despite the fact
that they had been admitted to and cared for in an ICU. This
group had an ICU mortality of 13.5%. The CURB-65 score
identified 113 patients as being at low risk with an observed
mortality of 19.4%. Seventy-three patients were likewise cat-
egorized by the PIRO-CAP score and these had a mortality
of 13.7%. Factors predicting death in these low-risk groups
are described in Table 5.
Discussion
This study shows that severity scores underestimate ICU
mortality in patients with 2009 Influenza A (H1N1) pneumo-
nia. This information, comparing three different scores, is
unique and adds value to the management of patients with
CAP during the influenza season.
Although PSI presented the best ability to predict mortal-
ity, calibration was poor, with all scores underestimating ICU
mortality (Fig. 2). PSI may underestimate severity, particularly
TABLE 2. Pneumonia severity scores
Score system Global Alive Death
Predicted
mortality
(%) p
PSI score (%)
Class I and II 70 (26.4) 64 (91.4) 6 (8.6) 0.1/0.6 <0.001
Class III 41 (15.5) 32 (78) 9 (22) 0.9
Class IV 79 (29.8) 49 (62) 30 (38) 9.5
Class V 75 (28.3) 36 (48) 39 (52) 26.7
CURB-65 score (%)
0 36 (13.6) 31 (86.1) 5 (13.9) 1.5 <0.001
1 77 (29.1) 60 (77.9) 17 (22.1) 1.5
2 93 (35.1) 62 (66.7) 31 (33.3) 9.2
3 37 (14) 20 (54.1) 17 (45.9) 22
4 21 (7.9) 7 (33.3) 14 (66.7) 22
5 1 (0.4) 1 (100) 0 (0) 22
PIRO-CAP score (%)
Low risk (0–2) 73 (27.5) 63 (86.3) 10 (13.7) 3.6 0.001
Mild risk (3) 77 (29.1) 52 (67.5) 25 (32.5) 13
High risk (4) 67 (25.3) 40 (59.7) 27 (40.3) 43
Very high (‡5) 48 (18.1) 26 (54.2) 22 (45.8) 76.3
TABLE 3. Severity scores according to presentation as either
a primary viral pneumonia or as a bacterial co-infection
Scores
Global
Only viral
pneumonia
Bacterial
co-infection
aROC 95% CI aROC 95% CI aROC 95% CI
PSI 0.72 0.65–0.78 0.73 0.65–0.81 0.72 0.47–0.73
APACHE II 0.68 0.60–0.75 0.65 0.56–0.74 0.75 0.64–0.86
CURB-65 0.67 0.59–0.74 0.62 0.53–0.72 0.77 0.66–0.87
SAPS 3 0.66 0.58–0.73 0.70 0.62–0.79 0.57 0.42–0.71
PIRO-CAP 0.64 0.56–0.71 0.65 0.56–0.74 0.60 0.47–0.73
TABLE 4. Sensitivity, specificity,
positive predicted value (PPV) and
negative predictive value (NPV) for
the evaluated scores
Score system Sensitivity Specificity PPV NPP
PSI
‡Class III 92.9 (87.4–98.4) 35.4 (28.4–42.3) 40 (33.1–46.9) 91.4 (84.9–97.9)
‡Class IV 82.1 (73.9–90.3) 53 (45.8–60.3) 44.8 (36.9–52.7) 86.5 (80.1–92.8)
‡Class V 46.4 (35.8–57.1) 80.1 (74.3–85.9) 52 (40.7–63.3) 76.3 (70.3–82.4)
CURB-65
‡1 94.1 (88.9–99.1) 17.1 (11.6–22.6) 34.5 (28.3–40.6) 86.1 (74.8–97.4)
‡2 73.8 (64.4–83.2) 50.3 (42.9–57.6) 40.8 (32.9–48.6) 80.5 (73.2–87.8)
‡3 36.9 (26.6–47.2) 84.5 (79.3–89.9) 52.5 (39.8–65.3) 74.3 (68.3–80.2)
‡4 16.7 (8.7–24.6) 95.6 (92.6–98.6) 63.6 (43.5–83.7) 71.2 (65.5–76.9)
‡5 0 99.4 (98.4–100) 0 68.2 (62.6–73.8)
PIRO-CAP
‡1 96.4 (92.5–100) 7.2 (3.4–10.9) 32.5 (26.7–38.3) 81.2 (62.1–100)
‡2 94.0 (88.9–99.1) 17.1 (11.6–22.6) 34.5 (28.3–40.6) 86.1 (74.8–97.4)
‡3 88.1 (81.2–95.0) 34.8 (27.9–41.8) 38.5 (31.7–45.4) 86.3 (78.4–94.2)
‡4 58.3 (47.8–68.9) 63.5 (56.6–70.5) 42.6 (33.6–51.6) 76.7 (69.9–83.4)
‡5 26.2 (16.8–35.6) 85.6 (80.5–90.7) 45.8 (31.7–59.9) 71.4 (65.4–77.4)
‡6 4.8 (0.2–9.3) 97.8 (95.6–99.9) 50 (15.3–84.6) 68.9 (63.2–74.5)
‡7 1.2 ()1.1–3.5) 99.4 (98.4–100) 50 ()19–119) 68.4 (62.8–74.1)
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in younger patients without co-morbidities who have severe
respiratory failure. Similarly, CURB-65 may also underesti-
mate risk in elderly patients with co-morbidities and in youn-
ger patients. As 2009 Influenza A (H1N1) infection occurred
mainly in young patients with co-morbidities this may be one
explanation for why these scores did not perform well. The
second possible explanation is that severe respiratory failure
was the main reason for ICU admission and all these scores
underestimate this issue.
In patients with primary viral pneumonia, the discrimina-
tory power of the different severity scores was reasonable
and PSI was the best predictor of mortality with an accept-
able discriminatory power (aROC 0.73). For patients with
bacterial co-infection, the CURB-65 showed the best ability
to predict ICU mortality. Neither of the general severity of
illness scores was able to match the discrimination of the
above two tools in these settings.
A scoring system with highest sensitivity is important in
order not to miss the sickest patients and to minimize
mortality. However, a very high sensitivity may also lead to a
high burden of false-positive results. Our results showed that
PIRO-CAP ‡ 1 had the highest sensitivity but PSI ‡ class III
and CURB-65 ‡ 1 also showed a very good sensitivity. In the
real world where ICU bed availability is a frequent problem,
the PPV appears to become most important as it defines the
proportion of patients severely ill who actually die. On this
basis, a CURB-65 ‡ 4 was superior to the other studied
scores yet none of them showed a significant result. Unlike
PSI, CURB-65 ‡ 4 and PIRO-CAP ‡ 6 presented a very high
specificity, 95.6% and 97.8%, respectively. In this study, PSI
class ‡ 3 (92.8%) showed the highest NPV as compared with
CURB-65 ‡ 1 (91.4%) and PIRO-CAP ‡ 3 (96.3%).
Our data discourage the use of these scores in patients
with CAP due to 2009 Influenza A (H1N1) virus in order to
decide site of treatment.
The accuracy of different pneumonia severity scores to pre-
dict ICU admission and hospital mortality in patients hospital-
ized for influenza was previously evaluated [14]. In this study,
neither PSI nor CURB-65 was a good predictor of in-hospital
mortality or ICU admission. Interestingly, their accuracy to
predict in-hospital mortality evaluated by aROC was not quite
different from their accuracy to predict ICU mortality in our
study. Branda˜o-Neto et al. [15] suggested in an observational
study of 53 patients hospitalized for pandemic 2009 Influenza
A (H1N1) that PSI and CURB-65 perform poorly in this
cohort of patients. In this study, these scores underestimate
severity because, as in our study, a significant number of
patients with low risk of mortality were admitted to the ICU.
In fact, they observed that ICU admission occurred in 36.8%
of the patients with a PSI score of I and II and in 49% of those
with a CURB-65 score of 0–1. These results extend those of
Mulrennan et al. [16] that the CURB-65 score, when applied
to 2009 Influenza A (H1N1) was not suitable for predicting
ICU admission. This is consistent with preliminary data
regarding 2009 H1N1 influenza pneumonia [17].
SAPS3 and APACHE II scores were significantly higher in
non-survivors than in survivors and this was also observed in
TABLE 5. Risk factors for mortality in low-risk patients
Severity score Variables
Univariate analysis Multivariate analysis
RR 95% CI p OR 95% CI p
PSI < 3 Other CPD 8.38 5.03–13.87 0.017 3.284 0.955–11.291 0.059
Septic shock 2.6 1.02–6.42 0.05 3.221 1.861–5.576 <0.001
Acute coronary syndrome 5.5 2.13–14.17 0.048 1.005 0.139–7.270 0.996
CURB 65 £ 1 Chemotherapy 3.4 1.50–7.77 0.05 7.393 1.629–33.552 0.01
Bacterial pneumonia 0.1 0.02–0.89 0.007 0.787 0.429–1.443 0.439
Rhabdomyolysis 2.8 1.34–5.72 0.017 2.248 1.090–4.638 0.028
Invasive mechanical ventilation 11.7 1.68–83.54 <0.001 27.102 5.966–123.123 <0.001
PIRO CAP £ 2 Other CPD 5.8 2.08–16.38 0.048 2.467 0.725–8.393 0.148
RR, relative risk; OR, odds ratio; 95% CI, 95% confidence interval.
FIG. 2. Discriminatory power of severity scores (aROC).
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other case series [18–21]. However, their predictive accu-
racy was not significantly better than pneumonia-specific
scores. In a study [22], APACHE II score showed a good
accuracy (aROC 0.84) in predicting severity in 2009 Influenza
A (H1N1). Yet, its application outside the ICU has not been
validated and its application to all patients in the emergency
department is complex.
All these scores do not perform well with regard to identi-
fication of patients with a low risk of death. In our low-risk
group of patients, risk factors associated with higher mortality
were severe respiratory failure (assumed to be the need for
mechanical ventilation), other chronic pulmonary disease than
COPD, chemotherapy and the presence of associated clinical
conditions such as septic shock, acute coronary syndrome
and rhabdomyolysis. Therefore, physicians should be cautious
about the management of low-risk patients if at least one of
the risk factors identified in this study is present. It is likely
that these patients should be admitted to the hospital (even-
tually to the ICU) and carefully reassessed in order to decide
on the best site of treatment. This is the first large study that
has evaluated the accuracy of several specific severity scores
in patients admitted to the ICU due to 2009 Influenza A
(H1N1) infection. As with all observational studies, this study
has several limitations. The PSI and CURB-65 were developed
and validated to be used in the emergency department and
not at ICU admission. Their use in patients already admitted
to an ICU changes the sampling space of the score and may
have introduced some discriminatory and calibration bias.
This is an important problem, as it introduces a major differ-
ence to the scores developed to be used in patients already
admitted to an ICU (e.g. the PIRO-CAP). Also, the volunteer
nature of the registry may have introduced a degree of selec-
tion bias in the development of the database.
Conclusions
In conclusion, our results suggest that severity of illness
scoring systems in ICU patients with CAP due to 2009 Influ-
enza A (H1N1) should not be used as a triage tool, as dem-
onstrated by a significant mortality rate even in patients
considered to be not meeting criteria for hospital admission.
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